Williamson, Anna E.
Liyanage, Sanuri
Hassanshahi, Mohammadhossein
Dona, Malathi S. I. http://orcid.org/0000-0002-0337-4417
Toledo-Flores, Deborah
Tran, Dang X. A.
Dimasi, Catherine
Schwarz, Nisha
Fernando, Sanuja
Salagaras, Thalia
Long, Aaron
Kazenwadel, Jan http://orcid.org/0000-0001-6216-3444
Harvey, Natasha L. http://orcid.org/0000-0001-9839-8966
Drummond, Grant R.
Vinh, Antony http://orcid.org/0000-0001-8367-6134
Chandrakanthan, Vashe http://orcid.org/0000-0002-4314-5029
Misra, Ashish
Neufeld, Zoltan
Tan, Joanne T. M. http://orcid.org/0000-0003-1875-4882
Martelotto, Luciano http://orcid.org/0000-0002-9625-1183
Polo, Jose M. http://orcid.org/0000-0002-2531-778X
Bonder, Claudine S. http://orcid.org/0000-0001-9875-967X
Pinto, Alexander R. http://orcid.org/0000-0001-6421-4970
Sharma, Shiwani
Nicholls, Stephen J.
Bursill, Christina A.
Psaltis, Peter J. http://orcid.org/0000-0003-0222-5468
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (CDF 1161506, PG 1086796, IG 2001541, PRF 1111630)
National Heart Foundation of Australia (100412, 102056, 106656, VG 102981)
Royal Australasian College of Physicians
Article History
Received: 20 December 2023
Accepted: 13 August 2024
First Online: 17 August 2024
Competing interests
: S.J.N. has received research support from AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and Liposcience and is a consultant for AstraZeneca, Akcea, Eli Lilly, Anthera, Kowa, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion and Boehringer Ingelheim. P.J.P. has received research support from Abbott Vascular, consulting fees from Amgen, Esperion, Eli Lilly, Novartis, Novo Nordisk and Sanofi, and speaker honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck Schering-Plough, Pfizer, Novartis, Novo Nordisk and Sanofi. The remaining authors declare no competing interests.